Forum Karczmy Bezdennego Kufla

cheapbag214s

Promising anti-flu drug under development
FORT BELVOIR, Va., Oct. 16 () -- An anti-flu drug being developed by the U.S. military and MediVector Inc. has successfully completed Phase 2 double blind placebo-controlled clinical trial.BioDefense Therapeutics, a joint product management office within the Department of Defense, said the Phase 2 trial showed twice daily dosing of the drug T-705a showed statistically significant decreases in time to alleviate of each of six influenza symptoms.In addition, subjects receiving T-705a cleared the virus more quickly compared to placebo."We are encouraged by this important achievement; it means [BioDefense Therapeutics] is one step closer to providing the military and our nation with safe therapeutics to counter biological threats,[url=http://www.outletonliner.com]prada outlet online[/url]," said Lt. Col. Eric G. Midboe,[url=http://www.outletonliner.com]gucci outlet online[/url], U.S. Army, joint product manager for BioDefense Therapeutics. "The rapidly evolving viral flu strains, especially the emergence of drug resistant strains, make a broad-spectrum drug solution essential in any strategy to combat this and similar biological threats." The military projects that a flu-like pandemic could infect nearly 10 percent of the nation's military personnel per month, significantly reducing military medical and operational capabilities.In vitro studies of T-705a show significant viral reductions against multiple flu viruses, including H1N1 (seasonal and 2009 pandemic), H5N1, H7N9 and drug-resistant flu strains."We are concerned with not only naturally occurring flu strains,[url=http://www.christianlouboutinoutletsvip.co.uk/]Christian Louboutin Sale[/url], but also those that may be biologically engineered," said Dr. Tyler Bennett,[url=http://www.guccioutletonlinen.com/]gucci outlet online[/url], assistant product manager for BioDefense Therapeutics. "T-705a has a unique mechanism of action that works by blocking viral RNA replication within the infected cell, giving T-705a the potential to be broad-spectrum."We intend to further test T-705a's efficacy against other viruses of interest to the [Department of Defense]."